Eyepoint Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative treatments for diseases affecting the eye, particularly those related to retinal and intraocular conditions. The company is dedicated to advancing sustained-release drug delivery systems, enabling patients to receive extended therapeutic benefits from their medications with reduced frequency of administration. Eyepoint's portfolio includes specialized formulations that aim to improve patient outcomes and ease the burden of disease management in ocular health. Through its commitment to research and development, Eyepoint seeks to address unmet medical needs in the field of ophthalmology. Read More
Eyepoint Pharmaceuticals (NASDAQ:EYPT) reported topline results from LUGANO, the first of two Phase III trials evaluating DURAVYU, a vorolanib intravitreal insert, in patients with wet age-related macular degeneration, or wet AMD. The study did not meet its primary non-inferiority endpoint in the fu
Eyepoint Pharmaceuticals (NASDAQ:EYPT) executives said the company remains on track to report top-line data from its Phase 3 wet age-related macular degeneration program for DURAVYU, also known as EYP-1901, beginning in August, with a second pivotal trial expected to follow about two months later.
The multi-billion dollar wet Age-Related Macular Degeneration (wet AMD) market is standing on the precipice of a transformative shift. Today, February 16, 2026, Ocular Therapeutix (NASDAQ: OCUL) is in its final "quiet period" before releasing the highly anticipated topline results for its SOL-1 Phase 3 trial. The data, expected to
The U.S. biotech sector has officially entered a new golden age. As of January 22, 2026, the industry is witnessing a "renaissance" that has effectively erased the memories of the grueling three-year downturn that plagued the market between 2022 and 2024. This resurgence is not merely a product of
In a dramatic shift that has recalibrated the pulse of Wall Street, the Russell 2000 index (RUT) surged to a new record high on January 8, 2026, signaling a definitive breakout for small-cap stocks. As investors aggressively rotate capital out of the overextended technology giants that dominated the previous three
As the opening bells of 2026 ring across Wall Street, a definitive shift in market leadership is unfolding. In the first trading sessions of the new year, the Russell 2000 index, a benchmark for small-cap stocks, has notably outperformed the tech-heavy S&P 500 and the Nasdaq Composite. This early-January
As the sun rises on January 1, 2026, the financial landscape is witnessing a profound shift that many analysts have anticipated for years: the definitive return of the U.S. small-cap sector. After a long period of living in the shadow of "Magnificent Seven" mega-caps, smaller domestic companies are finally
